Frankfurt
17.03.25 | 08:52
3,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | OPTHEA LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 17.04. | OPTHEA LIMITED: Long Term Suspended Entities | 1 | ASX | ||
| 01.03. | OPTHEA LIMITED: Appendix 4D and Half Year Report for period 31 Dec 2025 | 1 | ASX | ||
| 29.01. | OPTHEA LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
| 22.01. | OPTHEA LIMITED: Long Term Suspended Entities | 6 | ASX | ||
| 15.01. | OPTHEA LIMITED: Notification of cessation of securities - OPT | 2 | ASX | ||
| 22.12.25 | OPTHEA LIMITED: Change of Director's Interest Notice - KC & LG | - | ASX | ||
| 19.12.25 | OPTHEA LIMITED: Notification regarding unquoted securities - OPT | 1 | ASX | ||
| OPTHEA LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 17.12.25 | Health Check: No longer sheepish, Opthea flags fresh start | 3 | Stockhead | ||
| 17.12.25 | OPTHEA LIMITED: Investor Update Presentation | 2 | ASX | ||
| 11.12.25 | OPTHEA LIMITED: Notice of Market Update | 16 | ASX | ||
| 07.12.25 | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 20.11.25 | OPTHEA LIMITED: Voluntary delisting from Nasdaq takes effect | 1 | ASX | ||
| 20.11.25 | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 14,990 | +2,11 % | PALATIN TECHNOLOGIES INC - 10-Q, Quarterly Report | ||
| COSCIENS BIOPHARMA | 1,430 | +1,42 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 58,00 | +0,42 % | Halozyme Therapeutics, Inc.: Halozyme Reports First Quarter 2026 Results And Reiterates 2026 Financial Guidance | Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026
Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,520 | -0,42 % | AbCellera-Aktie vor Zahlen - setzt sich die Rallye weiter fort? | Die AbCellera-Aktie ist am vergangenen Freitag um rund +9% gestiegen und legte nachbörslich nochmals um weitere knapp +5% zu. Damit rücken die heutigen Quartalszahlen zunehmend in den Fokus, da der... ► Artikel lesen | |
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 212,40 | -0,38 % | Bio-Rad Laboratories Swings To Q4 Profit | WASHINGTON (dpa-AFX) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025.... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer | Experienced life sciences leader to drive global commercial strategy and accelerate growth across early- and late-phase biologics programsTUSTIN, Calif., May 11, 2026 /PRNewswire/ -- Avid... ► Artikel lesen | |
| BIOLINERX | 2,380 | -1,65 % | BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer CenterData... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 4,520 | +11,33 % | Whitehawk Therapeutics secures $87.5M PIPE financing | ||
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 4,424 | +0,82 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates | Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened
Previous open label trial data presented at SIRS 2026 showed no safety or drug-drug... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,360 | 0,00 % | B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target | ||
| COCRYSTAL | 1,070 | +2,88 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results | Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohortsHighlighted... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 6,850 | +9,42 % | Precision BioSciences stellt vielversprechende präklinische Daten zur DMD-Gentherapie vor |
OPTHEA LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTHEA LIMITED ADR finden Sie auf Wallstreet Online.